المؤلفون: Heumann, Philipp, Aguado-Barrera, Miguel E., Avuzzi, Barbara, Azria, David, Briers, Erik, Bultijnck, Renée, Choudhury, Ananya, De Ruysscher, Dirk, Farcy-Jacquet, Marie-Pierre, Fonteyne, Valerie, Gómez Caamaño, Antonio, Helmbold, Irmgard, Johnson, Kerstie, Kerns, Sarah L., Lambrecht, Maarten, Lingard, Zoe, Rancati, Tiziana, Rosenstein, Barry S., Sperk, Elena, Paul Symonds, R., Talbot, Christopher, Valdagni, Riccardo, Vega, Ana, Veldeman, Liv, Ward, Tim, Webb, Adam, West, Catharine M., Chang-Claude, Jenny, Seibold, Petra

المصدر: RADIOTHERAPY AND ONCOLOGY ; ISSN: 0167-8140 ; ISSN: 1879-0887

مصطلحات موضوعية: Medicine and Health Sciences, Radiology, Nuclear Medicine and imaging, Oncology, Hematology, Radiotherapy, Prostate cancer, Patient -reported outcomes, Adverse events, Agreement

الوصف: Introduction: Previous studies showed that healthcare professionals and patients had only moderate to low agreement on their assessment of treatment-related symptoms. We aimed to determine the levels of agreement in a large cohort of prostate cancer patients. Methods: Analyses were made of data from 1,756 prostate cancer patients treated with external beam radiotherapy (RT) and/or brachytherapy in Europe and the USA and recruited into the prospective mul-ticentre observational REQUITE study. Eleven pelvic symptoms at the end of RT were compared after translating patient-reported outcomes (PROs) into CTCAE-based healthcare professional ratings. Gwet's AC2 agreement coefficient and 95% confidence intervals were calculated for each symptom. To compare severity of grading between patients and healthcare professionals, percent agreement and deviations for each symptom were graphically depicted. Stratified and sensitivity analyses were conducted to identify potential influencing factors and to assess heterogeneity and robustness of results.Results: The agreement for the 11 pelvic symptoms varied from very good (AC2 > 0.8: haematuria, rectal bleeding, management of sphincter control) to poor agreement (AC2 <= 0.2: proctitis and urinary urgency). Fatigue had a negative impact on the agreement. Patients tended to grade symptoms more severely than healthcare professionals. Information on sexual dysfunction was missing more frequently in healthcare professional assessment than PROs. Conclusion: Agreement was better for observable than subjective symptoms, with patients usually grad-ing symptoms more severely than healthcare professionals. Our findings emphasize that PROs should complement symptom assessment by healthcare professionals and be taken into consideration for clin-ical decision-making to incorporate the patient perspective.(c) 2022 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 176 (2022) 109426 This is an open access article under the CC BY-NC-ND license ...

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/01GSA3TCNNBEGMM6V29JTV82NPTest; http://hdl.handle.net/1854/LU-01GSA3TCNNBEGMM6V29JTV82NPTest; http://doi.org/10.1016/j.radonc.2022.11.015Test; https://biblio.ugent.be/publication/01GSA3TCNNBEGMM6V29JTV82NP/file/01GV3ES7SYPCDYS3C83JQD4M6ETest

الإتاحة: https://doi.org/10.1016/j.radonc.2022.11.015Test
https://biblio.ugent.be/publication/01GSA3TCNNBEGMM6V29JTV82NPTest
http://hdl.handle.net/1854/LU-01GSA3TCNNBEGMM6V29JTV82NPTest
https://biblio.ugent.be/publication/01GSA3TCNNBEGMM6V29JTV82NP/file/01GV3ES7SYPCDYS3C83JQD4M6ETest

المؤلفون: Vakaet, Vincent, Deseyne, Pieter, Bultijnck, Renée, Post, Giselle, West, Catharine, Azria, David, Bourgier, Celine, Farcy-Jacquet, Marie-Pierre, Rosenstein, Barry, Green, Sheryl, de Ruysscher, Dirk, Sperk, Elena, Veldwijk, Marlon, Herskind, Carsten, De Santis, Maria Carmen, Rancati, Tiziana, Giandini, Tommaso, Chang-Claude, Jenny, Seibold, Petra, Lambrecht, Maarten, Weltens, Caroline, Janssens, Hilde, Vega, Ana, Taboada-Valladares, Maria Begoña, Aguado-Barrera, Miguel Elías, Reyes, Victoria, Altabas, Manuel, Gutiérrez-Enríquez, Sara, Monten, Christel, Van Hulle, Hans, Veldeman, Liv

المصدر: ACTA ONCOLOGICA ; ISSN: 0284-186X ; ISSN: 1651-226X

مصطلحات موضوعية: Medicine and Health Sciences, Radiology, Nuclear Medicine and imaging, Oncology, Hematology, General Medicine, dosimetry, health-related quality of life, radiotherapy toxicity, prone position, Breast cancer, QUALITY-OF-LIFE, MODULATED RADIATION-THERAPY, RANDOMIZED-TRIAL, EUROPEAN-ORGANIZATION, HEART-DISEASE, WHOLE, IRRADIATION, TOXICITY, LUNG, EXPOSURE

الوصف: ObjectiveMost patients receive whole breast radiotherapy in a supine position. However, two randomised trials showed lower acute toxicity in prone position. Furthermore, in most patients, prone positioning reduced doses to the organs at risk. To confirm these findings, we compared toxicity outcomes, photographic assessment, and dosimetry between both positions using REQUITE data.MethodsREQUITE is an international multi-centre prospective observational study that recruited 2069 breast cancer patients receiving radiotherapy. Data on toxicity, health-related quality of life (HRQoL), and dosimetry were collected, as well as a photographic assessment. A matched case control analysis compared patients treated prone (n = 268) versus supine (n = 493). Exact matching was performed for the use of intensity-modulated radiotherapy, boost, lymph node irradiation, chemotherapy and fractionation, and the nearest neighbour for breast volume. Primary endpoints were dermatitis at the end of radiotherapy, and atrophy and cosmetic outcome by photographic assessment at two years.ResultsAt the last treatment fraction, there was no significant difference in dermatitis (p = .28) or any HRQoL domain, but prone positioning increased the risk of breast oedema (p < .001). At 2 years, patients treated in prone position had less atrophy (p = .01), and higher body image (p < .001), and social functioning (p < .001) scores. The photographic assessment showed no difference in cosmesis at 2 years (p = .22). In prone position, mean heart dose (MHD) was significantly lower for left-sided patients (1.29 Gy vs 2.10 Gy, p < .001) and ipsilateral mean lung dose (MLD) was significantly lower for all patients (2.77 Gy vs 5.89 Gy, p < .001).ConclusionsProne radiotherapy showed lower MLD and MHD compared to supine position, although the risk of developing breast oedema during radiotherapy was higher. At 2 years the photographic assessment showed no difference in the cosmetic outcome, but less atrophy was seen in prone-treated patients and ...

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/01H8HT42Y57NC8CEKJYQ5G5BH9Test; http://hdl.handle.net/1854/LU-01H8HT42Y57NC8CEKJYQ5G5BH9Test; http://doi.org/10.1080/0284186x.2023.2240486Test; https://biblio.ugent.be/publication/01H8HT42Y57NC8CEKJYQ5G5BH9/file/01H95NWETG8Y9BFDNSSXW7NFQHTest

الإتاحة: https://doi.org/10.1080/0284186x.2023.2240486Test
https://biblio.ugent.be/publication/01H8HT42Y57NC8CEKJYQ5G5BH9Test
http://hdl.handle.net/1854/LU-01H8HT42Y57NC8CEKJYQ5G5BH9Test
https://biblio.ugent.be/publication/01H8HT42Y57NC8CEKJYQ5G5BH9/file/01H95NWETG8Y9BFDNSSXW7NFQHTest

المؤلفون: Jandu, Harkeran K., Veal, Colin D., Fachal, Laura, Luccarini, Craig, Aguado-Barrera, Miguel E., Altabas, Manuel, Azria, David, Baten, Adinda, Bourgier, Celine, Bultijnck, Renée, Colciago, Riccardo R., Farcy-Jacquet, Marie-Pierre, Chang-Claude, Jenny, Choudhury, Ananya, Dunning, Alison, Elliott, Rebecca M., Green, Sheryl, Gutiérrez-Enríquez, Sara, Herskind, Carsten, Lambrecht, Maarten, Monten, Christel, Rancati, Tiziana, Reyes, Victoria, Rosenstein, Barry S., De Ruysscher, Dirk, Carmen De Santis, Maria, Seibold, Petra, Sperk, Elena, Veldwijk, Marlon, Paul Symonds, R., Stobart, Hilary, Taboada-Valladares, Begoña, Vega, Ana, Veldeman, Liv, Webb, Adam J., Weltens, Caroline, West, Catharine M., Rattay, Tim, Talbot, Christopher J., Consortium, REQUITE

المصدر: RADIOTHERAPY AND ONCOLOGY ; ISSN: 0167-8140 ; ISSN: 1879-0887

مصطلحات موضوعية: Medicine and Health Sciences, Radiology, Nuclear Medicine and imaging, Oncology, Hematology, Breast Cancer, Radiotherapy, Radiotherapy side effects, Chronic toxicity, Genome-wide association study, Radiogenomics

الوصف: Background and purpose: Up to a quarter of breast cancer patients treated by surgery and radiotherapy experience clinically significant toxicity. If patients at high risk of adverse effects could be identified at diagnosis, their treatment could be tailored accordingly. This study was designed to identify common single nucleotide polymorphisms (SNPs) associated with toxicity two years following whole breast radiotherapy. Materials and Methods: A genome-wide association study (GWAS) was performed in 1,640 breast cancer patients with complete SNP, clinical, treatment and toxicity data, recruited across 18 European and US centres into the prospective REQUITE cohort study. Toxicity data (CTCAE v4.0) were collected at baseline, end of radiotherapy, and annual follow-up. A total of 7,097,340 SNPs were tested for association with the residuals of toxicity endpoints, adjusted for clinical, treatment co-variates and population substructure. Results: Quantile-quantile plots showed more associations with toxicity above the p 5 x 10-5 level than expected by chance. Eight SNPs reached genome-wide significance. Nipple retraction grade 2 was associated with the rs188287402 variant (p = 2.80 x 10-8), breastoedema grade > 2 with rs12657177 (p = 1. 12 x 10-10), rs75912034 (p = 1.12 x 10-10), rs145328458 (p = 1.06 x 10-9) and rs61966612 (p = 1.23 x 10- 9), induration grade > 2 with rs77311050 (p = 2.54 x 10-8) and rs34063419 (p = 1.21 x 10-8), and arm lymphoedema grade > 1 with rs643644 (p = 3.54 x 10-8). Heritability estimates across significant endpoints ranged from 25% to 39%. Our study did not replicate previously reported SNPs associated with breast radiation toxicity at the pre-specified significance level. Conclusions: This GWAS for long-term breast radiation toxicity provides further evidence for significant association of common SNPs with distinct toxicity endpoints. (c) 2023 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 187 (2023) 1-10 This is an open access article under the CC BY license ...

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/01H8HSXR14CP6Z8FACN7R156MHTest; http://hdl.handle.net/1854/LU-01H8HSXR14CP6Z8FACN7R156MHTest; http://doi.org/10.1016/j.radonc.2023.109806Test; https://biblio.ugent.be/publication/01H8HSXR14CP6Z8FACN7R156MH/file/01H8HT15C7M0GHHT5FYSQC6C7FTest

الإتاحة: https://doi.org/10.1016/j.radonc.2023.109806Test
https://biblio.ugent.be/publication/01H8HSXR14CP6Z8FACN7R156MHTest
http://hdl.handle.net/1854/LU-01H8HSXR14CP6Z8FACN7R156MHTest
https://biblio.ugent.be/publication/01H8HSXR14CP6Z8FACN7R156MH/file/01H8HT15C7M0GHHT5FYSQC6C7FTest

المؤلفون: Joel Monárrez‐Espino, Lourdes Romero‐Rodriguez, Gabriela Escamilla‐Asiain, Andrea Ellis‐Irigoyen, María del Pilar Cubría‐Juárez, Douglas Sematimba, Carlos Rodríguez‐Galindo, Lourdes Vega‐Vega

المصدر: Cancer Reports, Vol 6, Iss 2, Pp n/a-n/a (2023)

مصطلحات موضوعية: epidemiology, hematology, oncology, pediatric cancer, relapse, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Background Pediatric cancer incidence in Mexico is ~160/million/year with leukemias making 49.8% of the cases. While survival rates have been reported in various Mexican studies, no data is available from the Telethon Pediatric Oncology Hospital‐HITO, a nonprofit private institution specialized exclusively in comprehensive pediatric oncology care in the country that closely follows high‐income countries' advanced standards of cancer care. Aim To determine overall survival (OS) and relapse‐free survival (RFS) in patients treated at HITO between December 2013 and February 2018. Methods and results Secondary analysis of data extracted from medical records. It included 286 children aged 0–17 years diagnosed with various cancers grouped into three categories based on location: (1) Acute lymphoblastic leukemia (ALL), (2) tumors within the central nervous system (TWCNS), and (3) tumors outside the CNS (TOCNS). OS and RFS rates for patients who completed 1 (n = 230) and 3 (n = 132) years of follow‐up after admission were computed by sex, age, and cancer location, and separately for a subsample (1‐year = 191, 3‐years = 110) who fulfilled the HITO criteria (no prior treatment, underwent surgery/chemotherapy when indicated, and initiated therapy). TOCNS accounted for 45.1%, but ALL was the most frequent single diagnosis with 28%. Three‐year OS for patients with ALL, TWCNS, and TOCNS who fulfilled the HITO criteria were 91.9%, 86.7%, and 79.3%, respectively; for 3‐year RFS these were 89.2%, 60%, and 72.4%. Boys showed slightly higher OS and RFS, but no major differences or trends were seen by age group. Conclusion This study sets a relevant reference in terms of survival and relapse for children with cancer in Mexico treated at a private oncology center that uses a comprehensive and integrated therapeutic model.

العلاقة: https://doi.org/10.1002/cnr2.1702Test; https://doaj.org/toc/2573-8348Test; https://doaj.org/article/4ff9dbb7b4a649ff8107d99734dba640Test

الإتاحة: https://doi.org/10.1002/cnr2.1702Test
https://doaj.org/article/4ff9dbb7b4a649ff8107d99734dba640Test

المؤلفون: Jain, Preetesh, Nomie, Krystle, Kotlov, Nikita, Segodin, VitaIy, Hill, Holly, Ok, Chi Young, Fetooh, Ahmed, Kanagal-Shamanna, Rashmi, Vega, Francisco, Bagaev, Alexander, Fowler, Nathan, Flowers, Christopher R., Wang, Michael

المصدر: Blood Cancer Journal ; volume 13, issue 1 ; ISSN 2044-5385

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1038/s41408-023-00927-2Test
https://www.nature.com/articles/s41408-023-00927-2.pdfTest
https://www.nature.com/articles/s41408-023-00927-2Test

المؤلفون: Steiner, Raphael E., Parra, Edwin R., Vega, Francisco, Feng, Lei, Westin, Jason R., Neelapu, Sattva S., Strati, Paolo, Green, Michael R., Flowers, Christopher R., Solis, Luisa M., Wistuba, Ignacio I., Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B., Noorani, Mansoor, Marques-Piubelli, Mario L.

المساهمون: Lymphoma Research Foundation, University of Texas MD Anderson Cancer Center

المصدر: Experimental Hematology & Oncology ; volume 12, issue 1 ; ISSN 2162-3619

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

الوصف: Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, patients who have disease relapse have an unfavorable prognosis. Pre-treatment prognostic biomarkers in PMBCL are needed. In this retrospective study, we analyzed the clinical features and outcomes of PMBCL patients and their association with immune cell subpopulations identified by multiplex immunofluorescence at initial diagnosis. Two different antibody panels were used to assess macrophages in tissue biopsy specimens collected before the initiation of induction therapy. Twelve PMBCL patients, including five patients who had disease relapse, were included in the analysis. At a median follow-up time of 32.2 months, the median progression-free and overall survival durations were not reached. Our findings suggest that a high density of PD-L1 + macrophages is associated with favorable features, such as early disease stage and the absence of B-symptoms, and indicate that a high percentage of PD-L1 + macrophages and high densities of CD30 + PD-L1 + cells and CD30 + cells might be associated with a lower risk of relapse within 12 months of therapy initiation. Further studies are needed to develop a biomarker signature predictive of treatment response with therapeutic consequences for patients with newly diagnosed PMBCL.

الإتاحة: https://doi.org/10.1186/s40164-023-00396-0Test

المؤلفون: Mansouri, Larry, Thorvaldsdottir, Birna, Sutton, Lesley-Ann, Karakatsoulis, Georgios, Meggendorfer, Manja, Parker, Helen, Nadeu, Ferran, Brieghel, Christian, Laidou, Stamatia, Moia, Riccardo, Rossi, Davide, Catherwood, Mark, Kotaskova, Jana, Delgado, Julio, Rodríguez-Vicente, Ana E., Benito, Rocío, Rigolin, Gian Matteo, Bonfiglio, Silvia, Scarfo, Lydia, Mattsson, Mattias, Davis, Zadie, Gogia, Ajay, Rani, Lata, Baliakas, Panagiotis, Foroughi-Asl, Hassan, Jylhä, Cecilia, Skaftason, Aron, Rapado, Inmaculada, Miras, Fatima, Martinez-Lopez, Joaquín, de la Serna, Javier, Rivas, Jesús María Hernández, Thornton, Patrick, Larráyoz, María José, Calasanz, María José, Fésüs, Viktória, Mátrai, Zoltán, Bödör, Csaba, Smedby, Karin E., Espinet, Blanca, Puiggros, Anna, Gupta, Ritu, Bullinger, Lars, Bosch, Francesc, Tazón-Vega, Bárbara, Baran-Marszak, Fanny, Oscier, David, Nguyen-Khac, Florence, Zenz, Thorsten, Terol, Maria Jose

المصدر: Leukemia ; volume 37, issue 2, page 504-504 ; ISSN 0887-6924 1476-5551

مصطلحات موضوعية: Oncology, Cancer Research, Hematology

الإتاحة: https://doi.org/10.1038/s41375-023-01813-3Test
https://www.nature.com/articles/s41375-023-01813-3.pdfTest
https://www.nature.com/articles/s41375-023-01813-3Test

المؤلفون: Vega, D.M., Yee, L.M., McShane, L.M., Williams, P.M., Chen, L., Vilimas, T., Fabrizio, D., Funari, V., Newberg, J., Bruce, L.K., Chen, S.-J., Baden, J., Carl Barrett, J., Beer, P., Butler, M., Cheng, J.-H., Conroy, J., Cyanam, D., Eyring, K., Garcia, E., Green, G., Gregersen, V.R., Hellmann, M.D., Keefer, L.A., Lasiter, L., Lazar, A.J., Li, M.-C., MacConaill, L.E., Meier, K., Mellert, H., Pabla, S., Pallavajjalla, A., Pestano, G., Salgado, R., Samara, R., Sokol, E.S., Stafford, P., Budczies, J., Stenzinger, A., Tom, W., Valkenburg, K.C., Wang, X.Z., Weigman, V., Xie, M., Xie, Q., Zehir, A., Zhao, C., Zhao, Y., Stewart, M.D., Allen, J.

المصدر: Annals of Oncology ; volume 35, issue 1, page 145 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2023.07.005Test
https://api.elsevier.com/content/article/PII:S0923753423007706?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753423007706?httpAccept=text/plainTest

المؤلفون: Alaggio, R, Amador, C, Anagnostopoulos, I, Attygalle, AD, Araujo, IBDO, Berti, E, Bhagat, G, Borges, AM, Boyer, D, Calaminici, M, Chadburn, A, Chan, JKC, Cheuk, W, Chng, W-J, Choi, JK, Chuang, S-S, Coupland, SE, Czader, M, Dave, SS, De Jong, D, Du, M-Q, Elenitoba-Johnson, KS, Ferry, J, Geyer, J, Gratzinger, D, Guitart, J, Gujral, S, Harris, M, Harrison, CJ, Hartmann, S, Hochhaus, A, Jansen, PM, Karube, K, Kempf, W, Khoury, J, Kimura, H, Klapper, W, Kovach, AE, Kumar, S, Lazar, AJ, Lazzi, S, Leoncini, L, Leung, N, Leventaki, V, Li, X-Q, Lim, MS, Liu, W-P, Louissaint, A, Marcogliese, A, Medeiros, LJ, Michal, M, Miranda, RN, Mitteldorf, C, Montes-Moreno, S, Morice, W, Nardi, V, Naresh, KN, Natkunam, Y, Ng, S-B, Oschlies, I, Ott, G, Parrens, M, Pulitzer, M, Rajkumar, SV, Rawstron, AC, Rech, K, Rosenwald, A, Said, J, Sarkozy, C, Sayed, S, Saygin, C, Schuh, A, Sewell, W, Siebert, R, Sohani, AR, Tooze, R, Traverse-Glehen, A, Vega, F, Vergier, B, Wechalekar, AD, Wood, B, Xerri, L, Xiao, W

المصدر: 1748 ; 1720

مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Oncology, Hematology, ACUTE LYMPHOBLASTIC-LEUKEMIA, T-CELL-LYMPHOMA, CHRONIC LYMPHOCYTIC-LEUKEMIA, PREDOMINANT HODGKIN LYMPHOMA, MULTICENTRIC CASTLEMAN DISEASE, DIFFUSE FOLLICULAR LYMPHOMA, LYMPHOPROLIFERATIVE DISEASE, CLINICOPATHOLOGICAL FEATURES, LYMPHOPLASMACYTIC LYMPHOMA, GENETIC ALTERATIONS, Hematologic Neoplasms, Humans, Lymphoma, World Health Organization, Immunology, 1103 Clinical Sciences, 1112 Oncology and Carcinogenesis

الوصف: We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.

العلاقة: Leukemia; http://hdl.handle.net/10044/1/100567Test

الإتاحة: https://doi.org/10.1038/s41375-022-01620-2Test
http://hdl.handle.net/10044/1/100567Test

المؤلفون: Mansouri, Larry, Thorvaldsdottir, Birna, Sutton, Lesley-Ann, Karakatsoulis, Georgios, Meggendorfer, Manja, Parker, Helen, Nadeu, Ferran, Brieghel, Christian, Laidou, Stamatia, Moia, Riccardo, Rossi, Davide, Catherwood, Mark, Kotaskova, Jana, Delgado, Julio, Rodríguez-Vicente, Ana E., Benito, Rocío, Rigolin, Gian Matteo, Bonfiglio, Silvia, Scarfo, Lydia, Mattsson, Mattias, Davis, Zadie, Gogia, Ajay, Rani, Lata, Baliakas, Panagiotis, Foroughi-Asl, Hassan, Jylhä, Cecilia, Skaftason, Aron, Rapado, Inmaculada, Miras, Fatima, Martinez-Lopez, Joaquín, de la Serna, Javier, Rivas, Jesús María Hernández, Thornton, Patrick, Larráyoz, María José, Calasanz, María José, Fésüs, Viktória, Mátrai, Zoltán, Bödör, Csaba, Smedby, Karin E., Espinet, Blanca, Puiggros, Anna, Gupta, Ritu, Bullinger, Lars, Bosch, Francesc, Tazón-Vega, Bárbara, Baran-Marszak, Fanny, Oscier, David, Nguyen-Khac, Florence, Zenz, Thorsten, Terol, Maria Jose

المصدر: Leukemia ; volume 37, issue 2, page 339-347 ; ISSN 0887-6924 1476-5551

مصطلحات موضوعية: Oncology, Cancer Research, Hematology

الوصف: Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes ( BIRC3 , EGR2 , MYD88, NFKBIE , NOTCH1 , POT1 , SF3B1, TP53 , and XPO1 ) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.7%) patients at frequencies ranging from 2.3–9.8% with mutations in NOTCH1 being the most frequent. In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT. In multivariate analysis of Binet stage A patients, performed separately for IGHV-mutated (M-CLL) and unmutated CLL (U-CLL), a different spectrum of gene alterations independently predicted short TTFT within the two subgroups. While SF3B1 and XPO1 mutations were independent prognostic variables in both U-CLL and M-CLL, TP53 , BIRC3 and EGR2 aberrations were significant predictors only in U-CLL, and NOTCH1 and NFKBIE only in M-CLL. Our findings underscore the need for a compartmentalized approach to identify high-risk patients, particularly among M-CLL patients, with potential implications for stratified management.

الإتاحة: https://doi.org/10.1038/s41375-022-01802-yTest
https://www.nature.com/articles/s41375-022-01802-y.pdfTest
https://www.nature.com/articles/s41375-022-01802-yTest